FY2025 Earnings Forecast for Zoetis Issued By Zacks Research

Zoetis Inc. (NYSE:ZTS) – Equities research analysts at Zacks Research decreased their FY2025 earnings per share estimates for shares of Zoetis in a note issued to investors on Wednesday, January 8th. Zacks Research analyst E. Bagri now expects that the company will post earnings of $6.36 per share for the year, down from their previous estimate of $6.37. The consensus estimate for Zoetis’ current full-year earnings is $5.90 per share. Zacks Research also issued estimates for Zoetis’ Q4 2025 earnings at $1.59 EPS, Q4 2026 earnings at $1.79 EPS and FY2026 earnings at $6.97 EPS.

Several other research analysts have also issued reports on ZTS. Stifel Nicolaus reduced their target price on Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a research report on Tuesday. JPMorgan Chase & Co. upped their price objective on shares of Zoetis from $225.00 to $230.00 and gave the company an “overweight” rating in a report on Friday, October 11th. Leerink Partnrs upgraded shares of Zoetis to a “strong-buy” rating in a research note on Monday, December 2nd. UBS Group started coverage on shares of Zoetis in a research note on Monday, December 9th. They set a “neutral” rating and a $196.00 price target on the stock. Finally, Leerink Partners started coverage on shares of Zoetis in a research note on Monday, December 2nd. They set an “outperform” rating and a $215.00 price objective for the company. One investment analyst has rated the stock with a hold rating, nine have given a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $211.89.

Zoetis Stock Performance

Shares of ZTS stock opened at $163.30 on Friday. Zoetis has a 12-month low of $144.80 and a 12-month high of $200.53. The business’s fifty day simple moving average is $171.71 and its 200-day simple moving average is $180.14. The company has a current ratio of 3.69, a quick ratio of 2.27 and a debt-to-equity ratio of 1.26. The company has a market cap of $73.68 billion, a PE ratio of 30.70, a PEG ratio of 2.91 and a beta of 0.89.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Monday, November 4th. The company reported $1.58 EPS for the quarter, beating the consensus estimate of $1.46 by $0.12. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. The business had revenue of $2.40 billion during the quarter, compared to analyst estimates of $2.29 billion. During the same period in the prior year, the firm posted $1.36 earnings per share. The company’s quarterly revenue was up 11.6% on a year-over-year basis.

Zoetis Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, January 21st will be paid a dividend of $0.50 per share. The ex-dividend date is Tuesday, January 21st. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.22%. This is a positive change from Zoetis’s previous quarterly dividend of $0.43. Zoetis’s dividend payout ratio (DPR) is presently 37.59%.

Institutional Investors Weigh In On Zoetis

Several hedge funds have recently bought and sold shares of the stock. Darwin Wealth Management LLC acquired a new position in shares of Zoetis in the 3rd quarter valued at $31,000. First Personal Financial Services acquired a new position in shares of Zoetis in the third quarter worth about $33,000. Capital Performance Advisors LLP purchased a new stake in shares of Zoetis during the 3rd quarter worth about $33,000. Dunhill Financial LLC grew its position in shares of Zoetis by 80.6% during the 3rd quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock valued at $33,000 after acquiring an additional 75 shares during the period. Finally, Quarry LP increased its stake in shares of Zoetis by 273.2% in the 2nd quarter. Quarry LP now owns 209 shares of the company’s stock valued at $36,000 after purchasing an additional 153 shares in the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.